These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21321066)

  • 21. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
    Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
    Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
    Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
    Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Blasina A; Hallin J; Chen E; Arango ME; Kraynov E; Register J; Grant S; Ninkovic S; Chen P; Nichols T; O'Connor P; Anderes K
    Mol Cancer Ther; 2008 Aug; 7(8):2394-404. PubMed ID: 18723486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
    Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
    Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
    Matthews DJ; Yakes FM; Chen J; Tadano M; Bornheim L; Clary DO; Tai A; Wagner JM; Miller N; Kim YD; Robertson S; Murray L; Karnitz LM
    Cell Cycle; 2007 Jan; 6(1):104-10. PubMed ID: 17245119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
    Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
    Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
    Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
    Maude SL; Enders GH
    Cancer Res; 2005 Feb; 65(3):780-6. PubMed ID: 15705874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
    Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
    Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chk1-dependent S-M checkpoint delay in vertebrate cells is linked to maintenance of viable replication structures.
    Zachos G; Rainey MD; Gillespie DA
    Mol Cell Biol; 2005 Jan; 25(2):563-74. PubMed ID: 15632059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
    Syljuåsen RG; Sørensen CS; Hansen LT; Fugger K; Lundin C; Johansson F; Helleday T; Sehested M; Lukas J; Bartek J
    Mol Cell Biol; 2005 May; 25(9):3553-62. PubMed ID: 15831461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
    Xu H; Cheung IY; Wei XX; Tran H; Gao X; Cheung NK
    Int J Cancer; 2011 Oct; 129(8):1953-62. PubMed ID: 21154747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.
    Köpper F; Bierwirth C; Schön M; Kunze M; Elvers I; Kranz D; Saini P; Menon MB; Walter D; Sørensen CS; Gaestel M; Helleday T; Schön MP; Dobbelstein M
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16856-61. PubMed ID: 24082115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
    Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
    BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.